The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
The closing price of Cytek BioSciences Inc (NASDAQ: CTKB) was $4.99 for the day, down -4.04% from the previous closing price of $5.2. In other words, the price has decreased by -$4.04 from its previous closing price. On the day, 1.26 million shares were traded. CTKB stock price reached its highest trading level at $5.21 during the session, while it also had its lowest trading level at $4.92.
Ratios:
Our analysis of CTKB’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 4.48 and its Current Ratio is at 5.17. In the meantime, Its Debt-to-Equity ratio is 0.09 whereas as Long-Term Debt/Eq ratio is at 0.06.
On May 09, 2025, TD Cowen Downgraded its rating to Hold which previously was Buy but kept the price unchanged to $4.
Goldman Downgraded its Buy to Sell on January 31, 2025, whereas the target price for the stock was revised from $7 to $4.50.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jun 02 ’25 when McCombe William D. bought 35,000 shares for $2.78 per share. The transaction valued at 97,300 led to the insider holds 55,746 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CTKB now has a Market Capitalization of 638045504 and an Enterprise Value of 401137504. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.24 while its Price-to-Book (P/B) ratio in mrq is 1.69. Its current Enterprise Value per Revenue stands at 2.038 whereas that against EBITDA is -14.93.
Stock Price History:
The Beta on a monthly basis for CTKB is 1.30, which has changed by -0.26617646 over the last 52 weeks, in comparison to a change of 0.13506866 over the same period for the S&P500. Over the past 52 weeks, CTKB has reached a high of $7.30, while it has fallen to a 52-week low of $2.37. The 50-Day Moving Average of the stock is 11.59%, while the 200-Day Moving Average is calculated to be 28.15%.
Shares Statistics:
CTKB traded an average of 1.14M shares per day over the past three months and 1211480 shares per day over the past ten days. A total of 127.86M shares are outstanding, with a floating share count of 115.90M. Insiders hold about 9.36% of the company’s shares, while institutions hold 62.79% stake in the company. Shares short for CTKB as of 1763078400 were 6639767 with a Short Ratio of 5.83, compared to 1760486400 on 6276347. Therefore, it implies a Short% of Shares Outstanding of 6639767 and a Short% of Float of 6.74.
Earnings Estimates
The stock of Cytek BioSciences Inc (CTKB) is currently drawing attention from 2.0 analysts actively involved in the ongoing evaluation and rating process.The consensus estimate for the next quarter is -$0.04, with high estimates of -$0.04 and low estimates of -$0.04.
Analysts are recommending an EPS of between $0.04 and -$0.01 for the fiscal current year, implying an average EPS of $0.01. EPS for the following year is -$0.01, with 2.0 analysts recommending between -$0.01 and -$0.02.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 4 analysts. It ranges from a high estimate of $58.76M to a low estimate of $55.4M. As of. The current estimate, Cytek BioSciences Inc’s year-ago sales were $57.48MFor the next quarter, 4 analysts are estimating revenue of $44.1M. There is a high estimate of $44.9M for the next quarter, whereas the lowest estimate is $42.62M.
A total of 5 analysts have provided revenue estimates for CTKB’s current fiscal year. The highest revenue estimate was $198.11M, while the lowest revenue estimate was $196M, resulting in an average revenue estimate of $196.71M. In the same quarter a year ago, actual revenue was $200.45MBased on 5 analysts’ estimates, the company’s revenue will be $207.45M in the next fiscal year. The high estimate is $211.82M and the low estimate is $203.3M.
